Producing sufficient capital is one of many challenges specific to the biotechnology industry. Launching just one new drug can cost in excess of $500 million and take decades to go from research to distribution. This endless endeavor of attracting much-needed capital from stakeholders produces a slew of complex regulations with which biotech executives must contend.
As a PCAOB-registered accounting firm focused on emerging companies in the public markets, we assist our clients in managing accounting and financial functions from a practical perspective. Our biotechnology accounting specialists can show you how to address “lower priority” accounting issues as well as establish and maintain business critical functions unique to the life sciences industries.
Boost Confidence In Your Business
Our extensive SEC and public company experience allow us to guide you through what can appear to be a maze of daunting regulatory issues, registration statements, reverse mergers, accounting methods, and internal controls. We can advise on appropriate accounting practices that can boost the confidence of your shareholders, customers, and executives and identify inefficient procedures that can reduce your company’s credibility and capital raising opportunities.
Our professionals have the technical and industry knowledge to efficiently assess development stage and biotechnology-specific issues such as:
- Revenue recognition and sales allowance
- Pre-launch inventory
- In-process research and development
- Research and collaboration arrangements
- Patents and other intangible assets
- Complex debt and equity arrangements
- Share-based compensation